Palouse Capital Management Trimmed Abbvie (ABBV) Holding; 12 Bullish Analysts Covering YY Inc. (YY)

March 19, 2018 - By Richard Conner

Palouse Capital Management Inc decreased Abbvie Inc (ABBV) stake by 39.99% reported in 2017Q3 SEC filing. Palouse Capital Management Inc sold 44,915 shares as Abbvie Inc (ABBV)’s stock rose 6.17%. The Palouse Capital Management Inc holds 67,410 shares with $5.99M value, down from 112,325 last quarter. Abbvie Inc now has $179.00B valuation. The stock decreased 0.87% or $0.99 during the last trading session, reaching $112.72. About 2.61 million shares traded. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since March 19, 2017 and is uptrending. It has underperformed by 6.07% the S&P500.

Among 13 analysts covering YY Inc (NASDAQ:YY), 12 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. YY Inc had 23 analyst reports since August 17, 2015 according to SRatingsIntel. The stock of YY Inc. (NASDAQ:YY) earned “Buy” rating by Bank of America on Tuesday, July 4. The firm earned “Overweight” rating on Friday, August 14 by Piper Jaffray. As per Monday, August 17, the company rating was downgraded by Pacific Crest. The firm has “Hold” rating given on Tuesday, October 3 by Jefferies. The stock of YY Inc. (NASDAQ:YY) has “Buy” rating given on Thursday, November 16 by J.P. Morgan. The firm earned “Hold” rating on Friday, June 16 by Jefferies. UBS initiated the stock with “Buy” rating in Tuesday, January 2 report. The stock of YY Inc. (NASDAQ:YY) has “Overweight” rating given on Thursday, November 16 by JP Morgan. Jefferies upgraded YY Inc. (NASDAQ:YY) on Wednesday, November 15 to “Buy” rating. Instinet upgraded YY Inc. (NASDAQ:YY) on Thursday, January 18 to “Buy” rating. See YY Inc. (NASDAQ:YY) latest ratings:

06/03/2018 Broker: Benchmark Rating: Buy New Target: $180.0
06/03/2018 Broker: CLSA Old Rating: Buy New Rating: Outperform Downgrade
20/02/2018 Broker: Citigroup Rating: Buy New Target: $150.0 Initiate
23/01/2018 Broker: Jefferies Rating: Buy New Target: $158.0 Maintain
17/01/2018 Broker: Nomura Rating: Buy Upgrade
18/01/2018 Broker: Instinet Old Rating: Neutral New Rating: Buy Upgrade
02/01/2018 Broker: UBS Rating: Buy New Target: $135.0 Initiate
16/11/2017 Broker: J.P. Morgan Rating: Buy New Target: $140.0 Upgrade
16/11/2017 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Upgrade
15/11/2017 Broker: Jefferies Old Rating: Hold New Rating: Buy Old Target: $45 Upgrade

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 10 have Buy rating, 2 Sell and 9 Hold. Therefore 48% are positive. Abbvie Inc had 79 analyst reports since July 21, 2015 according to SRatingsIntel. Barclays Capital maintained AbbVie Inc. (NYSE:ABBV) on Friday, October 13 with “Equal-Weight” rating. The stock of AbbVie Inc. (NYSE:ABBV) has “Buy” rating given on Friday, August 18 by Jefferies. The firm has “Neutral” rating by JP Morgan given on Thursday, September 8. The rating was upgraded by Morgan Stanley to “Overweight” on Monday, November 2. As per Tuesday, September 5, the company rating was maintained by Cowen & Co. The firm has “Hold” rating given on Monday, January 29 by Credit Suisse. UBS maintained it with “Buy” rating and $78 target in Friday, October 23 report. The rating was initiated by Societe Generale on Wednesday, April 6 with “Sell”. On Tuesday, October 18 the stock rating was initiated by Leerink Swann with “Mkt Perform”. Cowen & Co downgraded the shares of ABBV in report on Monday, June 6 to “Market Perform” rating.

Investors sentiment decreased to 0.8 in 2017 Q3. Its down 0.05, from 0.85 in 2017Q2. It is negative, as 55 investors sold ABBV shares while 640 reduced holdings. 132 funds opened positions while 462 raised stakes. 1.06 billion shares or 1.89% more from 1.04 billion shares in 2017Q2 were reported. Jarislowsky Fraser Ltd reported 259,444 shares. Nippon Life holds 307,368 shares. Schulhoff & reported 23,912 shares. Sumitomo Mitsui Tru Hldg stated it has 4.51 million shares. Deprince Race & Zollo holds 0.71% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 354,027 shares. Cibc World Mkts holds 244,984 shares or 0.21% of its portfolio. Burney owns 157,218 shares for 0.75% of their portfolio. 52,500 are held by Knott David M. Connors Investor Serv reported 1.04% of its portfolio in AbbVie Inc. (NYSE:ABBV). Geller Family Office Service Ltd reported 2,300 shares. Umb Bancshares N A Mo has 0.61% invested in AbbVie Inc. (NYSE:ABBV) for 200,801 shares. Kempen Cap Management Nv has invested 2.18% in AbbVie Inc. (NYSE:ABBV). Virginia-based Hendershot Invs Incorporated has invested 5.63% in AbbVie Inc. (NYSE:ABBV). Focused Wealth Mngmt reported 2,217 shares. Peapack Gladstone accumulated 0.83% or 162,435 shares.

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on April, 26. They expect $1.78 EPS, up 39.06% or $0.50 from last year’s $1.28 per share. ABBV’s profit will be $2.83 billion for 15.83 P/E if the $1.78 EPS becomes a reality. After $1.48 actual EPS reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 20.27% EPS growth.

Since September 28, 2017, it had 0 buys, and 13 selling transactions for $49.94 million activity. Another trade for 1,337 shares valued at $157,458 was made by SALEKI-GERHARDT AZITA on Wednesday, February 28. 70,928 shares valued at $8.31 million were sold by CHASE WILLIAM J on Wednesday, February 28. GONZALEZ RICHARD A sold 8,280 shares worth $976,084. Schumacher Laura J sold $2.95 million worth of stock. Michael Robert A. had sold 6,699 shares worth $589,512 on Thursday, September 28. $1.66M worth of AbbVie Inc. (NYSE:ABBV) was sold by Gosebruch Henry O. 18,129 AbbVie Inc. (NYSE:ABBV) shares with value of $2.15M were sold by RICHMOND TIMOTHY J..

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Richard Conner

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts